SCHEMBL27201490

SCHEMBL27201490

CN(C)CCNCc1n[nH]c2ccc(-c3ccc4ccnc(N)c4c3)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 4/20 0.44
DYRK1A Q13627 6/20 0.43
WNT1 P04628 4/20 0.43
JAK2 O60674 6/20 0.38
PIM1 P11309 2/20 0.37
PIM3 Q86V86 2/20 0.37
PIM2 Q9P1W9 2/20 0.37
PDPK1 O15530 1/20 0.37
ROCK1 Q13464 3/20 0.36
CLK2 P49760 3/20 0.36
PLK4 O00444 2/20 0.36
DAPK3 O43293 2/20 0.36
DYRK3 O43781 2/20 0.36
ROCK2 O75116 2/20 0.36
CDK1 P06493 2/20 0.36
CDK2 P24941 2/20 0.36
MARK3 P27448 2/20 0.36
TYK2 P29597 2/20 0.36
JAK3 P52333 2/20 0.36
CDK5 Q00535 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27201405 0.81 DYRK1A (0.67) DYRK1AWNT1CLK2CLK3
SCHEMBL27201494 0.73 DYRK1A (0.56) MAP4K4DYRK1AWNT1PDPK1CLK2
SCHEMBL30834135 0.73 DYRK1A (0.56) MAP4K4DYRK1AWNT1PDPK1CLK2
SCHEMBL26889247 0.71 CCNK (0.54) MAP4K4DYRK1AWNT1JAK2PIM1
SCHEMBL27201421 0.69 DYRK1A (0.50) DYRK1AWNT1CLK2CLK3
SCHEMBL30885290 0.67 PRKD3 (0.45) MAP4K4DYRK1AWNT1JAK2CLK2
SCHEMBL29122272 0.66 CFD (0.46) JAK2
SCHEMBL30834169 0.66 CHEK2 (0.47) MAP4K4DYRK1AWNT1JAK2TYK2
SCHEMBL30834072 0.66 CLK1 (0.55) MAP4K4DYRK1AJAK2PIM1PIM3
SCHEMBL27201611 0.66 CLK1 (0.55) MAP4K4DYRK1AJAK2PIM1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US claimed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO claimed
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP MAP4K4 1878/4885DYRK1A 2404/4885WNT1 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.